Skip to main content

19.04.2024 | Review Article

Management of Extraocular Retinoblastoma: ICMR Consensus Guidelines

verfasst von: Renu Madan, Venkatraman Radhakrishnan, Rachna Meel, Girish Chinnaswamy, Lata Singh, Suyash Kulkarni, Archana Sasi, Tanvir Kaur, Jyoti Sharma, R. S. Dhaliwal, Meena Haldorai, Gaura Kishore Rath, Sameer Bakhshi

Erschienen in: Indian Journal of Pediatrics

Einloggen, um Zugang zu erhalten

Abstract

Retinoblastoma (RB) is the most common intraocular malignancy of childhood. Advanced stage presentation of RB is common in low middle-income countries (LMICs) due to lack of awareness, social taboos associated with enucleation, seeking alternative conservative treatment options, and poor accessibility to health care. Over the last few decades, there have been significant advancements in the management of extraocular RB (EORB) which have improved outcomes and helped in minimizing treatment-related toxicities. The incorporation of multimodality approaches including chemotherapy, surgery, and radiotherapy (RT) has shown promising results; however, prognosis remains poor especially in LMICs. In this article, authors have discussed the ICMR consensus guidelines on the management of EORB, including metastatic RB.
Literatur
1.
Zurück zum Zitat Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93:1129–31.PubMedCrossRef Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93:1129–31.PubMedCrossRef
2.
Zurück zum Zitat Chantada G, Doz F, Antoneli CBG, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47:801–5.PubMedCrossRef Chantada G, Doz F, Antoneli CBG, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47:801–5.PubMedCrossRef
3.
Zurück zum Zitat Fabian ID, Abdallah E, Addullahi SU, et al; Global Retinoblastoma Study Group. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020;6:685–95.PubMedCrossRef Fabian ID, Abdallah E, Addullahi SU, et al; Global Retinoblastoma Study Group. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020;6:685–95.PubMedCrossRef
4.
Zurück zum Zitat Malhotra RK, Manoharan N, Nair O, Deo SVS, Bakhshi S, Rath GK. Patterns and trends of childhood cancer incidence (0–14 years) in Delhi, India: 1990–2014. Indian Pediatr. 2021;58:430–5.PubMedCrossRef Malhotra RK, Manoharan N, Nair O, Deo SVS, Bakhshi S, Rath GK. Patterns and trends of childhood cancer incidence (0–14 years) in Delhi, India: 1990–2014. Indian Pediatr. 2021;58:430–5.PubMedCrossRef
5.
Zurück zum Zitat Bakhshi S, Gupta S, Gogia V, Ravindranath Y. Compliance in retinoblastoma. Indian J Pediatr. 2010;77:535–40.PubMedCrossRef Bakhshi S, Gupta S, Gogia V, Ravindranath Y. Compliance in retinoblastoma. Indian J Pediatr. 2010;77:535–40.PubMedCrossRef
7.
Zurück zum Zitat Radhakrishnan V, Sharma S, Vishnubhatla S, Bakhshi S. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). Br J Ophthalmol. 2013;97:52–8.PubMedCrossRef Radhakrishnan V, Sharma S, Vishnubhatla S, Bakhshi S. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). Br J Ophthalmol. 2013;97:52–8.PubMedCrossRef
9.
Zurück zum Zitat Wiwatwongwana D, Kulniwatcharoen P, Mahanupab P, Visrutaratna P, Wiwatwongwana A. Accuracy of computed tomography and magnetic resonance imaging for detection of pathologic risk factors in patients diagnosed with retinoblastoma. Curr Eye Res. 2021;46:1544–50.PubMedCrossRef Wiwatwongwana D, Kulniwatcharoen P, Mahanupab P, Visrutaratna P, Wiwatwongwana A. Accuracy of computed tomography and magnetic resonance imaging for detection of pathologic risk factors in patients diagnosed with retinoblastoma. Curr Eye Res. 2021;46:1544–50.PubMedCrossRef
10.
Zurück zum Zitat Cho SJ, Kim JH, Baik SH, Sunwoo L, Bae YJ, Choi BS. Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: a systematic review and meta-analysis. Neuroradiology. 2021;63:499–509.PubMedCrossRef Cho SJ, Kim JH, Baik SH, Sunwoo L, Bae YJ, Choi BS. Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: a systematic review and meta-analysis. Neuroradiology. 2021;63:499–509.PubMedCrossRef
11.
Zurück zum Zitat Bakhshi S, Meel R, Kashyap S, Sharma S. Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlation with IRSS staging. J Pediatr Hematol Oncol. 2011;33:e182–5.PubMedCrossRef Bakhshi S, Meel R, Kashyap S, Sharma S. Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlation with IRSS staging. J Pediatr Hematol Oncol. 2011;33:e182–5.PubMedCrossRef
12.
Zurück zum Zitat Radhakrishnan V, Kumar R, Malhotra A, Bakhshi S. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. J Nucl Med. 2012;53:191–8.PubMedCrossRef Radhakrishnan V, Kumar R, Malhotra A, Bakhshi S. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. J Nucl Med. 2012;53:191–8.PubMedCrossRef
13.
Zurück zum Zitat Gündüz K, Müftüoglu O, Günalp I, Unal E, Taçyildiz N. Metastatic retinoblastoma: clinical features, treatment and prognosis. Ophthalmology. 2006;113:1558–66.PubMedCrossRef Gündüz K, Müftüoglu O, Günalp I, Unal E, Taçyildiz N. Metastatic retinoblastoma: clinical features, treatment and prognosis. Ophthalmology. 2006;113:1558–66.PubMedCrossRef
14.
Zurück zum Zitat Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40:158–61.PubMedCrossRef Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40:158–61.PubMedCrossRef
15.
Zurück zum Zitat Antoneli CBG, Steinhorst F, de Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98:1292–8.PubMedCrossRef Antoneli CBG, Steinhorst F, de Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98:1292–8.PubMedCrossRef
16.
Zurück zum Zitat Antoneli CBG, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cispla-tin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29:700–4.PubMedCrossRef Antoneli CBG, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cispla-tin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29:700–4.PubMedCrossRef
17.
Zurück zum Zitat Radhakrishnan V, Kashyap S, Pushker N, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology. 2012;119:1470–7.PubMedCrossRef Radhakrishnan V, Kashyap S, Pushker N, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology. 2012;119:1470–7.PubMedCrossRef
18.
Zurück zum Zitat Meel R, Bakhshi S, Pushker N, Vishnubhatia S. Randomized, controlled trial in groups C and D retinoblastoma. Ophthalmology. 2015;122:433–5.PubMedCrossRef Meel R, Bakhshi S, Pushker N, Vishnubhatia S. Randomized, controlled trial in groups C and D retinoblastoma. Ophthalmology. 2015;122:433–5.PubMedCrossRef
19.
Zurück zum Zitat Jaradat I, Mubiden R, Salem A, Abdel-Rahman F, Al-Ahmad I, Almousa A. High-dose chemotherapy followed by stem cell transplantation in the management of retinoblastoma: a systematic review. Hematol Oncol Stem Cell Ther. 2012;5:107–17.PubMedCrossRef Jaradat I, Mubiden R, Salem A, Abdel-Rahman F, Al-Ahmad I, Almousa A. High-dose chemotherapy followed by stem cell transplantation in the management of retinoblastoma: a systematic review. Hematol Oncol Stem Cell Ther. 2012;5:107–17.PubMedCrossRef
20.
Zurück zum Zitat Dunkel IJ, Chan HSL, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55:149–52.PubMedCrossRef Dunkel IJ, Chan HSL, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55:149–52.PubMedCrossRef
21.
Zurück zum Zitat Rodriguez A, Zugbi S, Requejo F, et al. Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma. Pediatr Blood Cancer. 2018;65:e27385.PubMedCrossRef Rodriguez A, Zugbi S, Requejo F, et al. Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma. Pediatr Blood Cancer. 2018;65:e27385.PubMedCrossRef
22.
Zurück zum Zitat Hu H, Zhang W, Wang Y, et al. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC Ophthalmol. 2018;18:107.PubMedPubMedCentralCrossRef Hu H, Zhang W, Wang Y, et al. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC Ophthalmol. 2018;18:107.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Chantada GL, Dunkel IJ, de Dávila MTG, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069–73.PubMedPubMedCentralCrossRef Chantada GL, Dunkel IJ, de Dávila MTG, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069–73.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122:1316–23.PubMedCrossRef Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122:1316–23.PubMedCrossRef
25.
Zurück zum Zitat Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923–31.PubMedCrossRef Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923–31.PubMedCrossRef
26.
Zurück zum Zitat Singh U, Katoch D, Kaur S, Dogra MR, Bansal D, Kapoor R. Retinoblastoma: a sixteen-year review of the presentation, treatment, and outcome from a tertiary care institute in northern India. Ocul Oncol Pathol. 2017;4:23–32.PubMedPubMedCentralCrossRef Singh U, Katoch D, Kaur S, Dogra MR, Bansal D, Kapoor R. Retinoblastoma: a sixteen-year review of the presentation, treatment, and outcome from a tertiary care institute in northern India. Ocul Oncol Pathol. 2017;4:23–32.PubMedPubMedCentralCrossRef
27.
28.
Zurück zum Zitat Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31:1458–63.PubMedCrossRef Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31:1458–63.PubMedCrossRef
29.
Zurück zum Zitat Foote RL, Garretson BR, Schomberg PJ, Buskirk SJ, Robertson DM, Earle JD. External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis. Int J Radiat Oncol Biol Phys. 1989;16:823–30.PubMedCrossRef Foote RL, Garretson BR, Schomberg PJ, Buskirk SJ, Robertson DM, Earle JD. External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis. Int J Radiat Oncol Biol Phys. 1989;16:823–30.PubMedCrossRef
30.
Zurück zum Zitat Abramson DH, Frank CM. Second non-ocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573–9.PubMedCrossRef Abramson DH, Frank CM. Second non-ocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573–9.PubMedCrossRef
31.
Zurück zum Zitat Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35:763–6.PubMedCrossRef Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35:763–6.PubMedCrossRef
32.
Zurück zum Zitat Dunkel IJ, Piao J, Chantada GL, et al. Intensive multimodality therapy for extraocular retinoblastoma: A Children’s Oncology Group Trial (ARET0321). J Clin Oncol. 2022;40:3839–47.PubMedPubMedCentralCrossRef Dunkel IJ, Piao J, Chantada GL, et al. Intensive multimodality therapy for extraocular retinoblastoma: A Children’s Oncology Group Trial (ARET0321). J Clin Oncol. 2022;40:3839–47.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology. 2003;110:1237–40.PubMedCrossRef Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology. 2003;110:1237–40.PubMedCrossRef
34.
Zurück zum Zitat Tsang DS, Vargo JA, Goddard K, Breneman JC, Kalapurakal JA, Marcus KJ. Palliative radiation therapy for children with cancer. Pediatr Blood Cancer. 2021;68:e28292.PubMedCrossRef Tsang DS, Vargo JA, Goddard K, Breneman JC, Kalapurakal JA, Marcus KJ. Palliative radiation therapy for children with cancer. Pediatr Blood Cancer. 2021;68:e28292.PubMedCrossRef
35.
Zurück zum Zitat Kim JW, Kathpalia V, Dunkel IJ, Wong RK, Riedel E, Abramson DH. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol. 2009;93:463–7.PubMedCrossRef Kim JW, Kathpalia V, Dunkel IJ, Wong RK, Riedel E, Abramson DH. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol. 2009;93:463–7.PubMedCrossRef
36.
Zurück zum Zitat Brennan RC, Qaddoumi I, Mao S, et al. Ocular salvage and vision preservation using a topotecan-based regimen for advanced intraocular retinoblastoma. J Clin Oncol. 2017;35:72–7.PubMedCrossRef Brennan RC, Qaddoumi I, Mao S, et al. Ocular salvage and vision preservation using a topotecan-based regimen for advanced intraocular retinoblastoma. J Clin Oncol. 2017;35:72–7.PubMedCrossRef
37.
Zurück zum Zitat Pramanik R, Bakhshi S. Metronomic therapy in pediatric oncology: a snapshot. Pediatr Blood Cancer. 2019;66:e27811.PubMedCrossRef Pramanik R, Bakhshi S. Metronomic therapy in pediatric oncology: a snapshot. Pediatr Blood Cancer. 2019;66:e27811.PubMedCrossRef
38.
Zurück zum Zitat Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. Indian J Pediatr. 2012;79:1617–22.PubMedCrossRef Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. Indian J Pediatr. 2012;79:1617–22.PubMedCrossRef
39.
Zurück zum Zitat Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol. 2017;3:1222–7.PubMedPubMedCentralCrossRef Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol. 2017;3:1222–7.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Kumar K, Radhakrishnan V, Dhanushkodi M, et al. Oral etoposide and cyclophosphamide: a low-cost palliative metronomic chemotherapy in advanced pediatric cancers. Cancer Res Stat Treat. 2020;3:64–8.CrossRef Kumar K, Radhakrishnan V, Dhanushkodi M, et al. Oral etoposide and cyclophosphamide: a low-cost palliative metronomic chemotherapy in advanced pediatric cancers. Cancer Res Stat Treat. 2020;3:64–8.CrossRef
41.
Zurück zum Zitat Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.PubMedCrossRef Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.PubMedCrossRef
42.
Zurück zum Zitat de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivelä T, Moll AC. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1157–67.PubMedCrossRef de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivelä T, Moll AC. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1157–67.PubMedCrossRef
43.
Zurück zum Zitat Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100:1771–9.PubMedCrossRef Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100:1771–9.PubMedCrossRef
44.
Zurück zum Zitat Batra A, Kain R, Kumari M, Paul R, Dhawan D, Bakhshi S. Parents’ perspective of quality of life of retinoblastoma survivors. Pediatr Blood Cancer. 2016;63:1287–9.PubMedCrossRef Batra A, Kain R, Kumari M, Paul R, Dhawan D, Bakhshi S. Parents’ perspective of quality of life of retinoblastoma survivors. Pediatr Blood Cancer. 2016;63:1287–9.PubMedCrossRef
45.
Zurück zum Zitat Batra A, Thakar A, Bakhshi S. Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: a cross-sectional study of 116 patients. Pediatr Blood Cancer. 2015;62:2060.PubMedCrossRef Batra A, Thakar A, Bakhshi S. Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: a cross-sectional study of 116 patients. Pediatr Blood Cancer. 2015;62:2060.PubMedCrossRef
Metadaten
Titel
Management of Extraocular Retinoblastoma: ICMR Consensus Guidelines
verfasst von
Renu Madan
Venkatraman Radhakrishnan
Rachna Meel
Girish Chinnaswamy
Lata Singh
Suyash Kulkarni
Archana Sasi
Tanvir Kaur
Jyoti Sharma
R. S. Dhaliwal
Meena Haldorai
Gaura Kishore Rath
Sameer Bakhshi
Publikationsdatum
19.04.2024
Verlag
Springer India
Erschienen in
Indian Journal of Pediatrics
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-024-05104-2

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.